Search results
$2.21
- Vera Therapeutics has generated ($2.21) earnings per share over the last year (($2.21) diluted earnings per share). Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.57) to ($2.85) per share.
www.marketbeat.com/stocks/NASDAQ/VERA/earnings/
Find the latest Vera Therapeutics, Inc. (VERA) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Analysis
See Vera Therapeutics, Inc. (VERA) stock analyst estimates,...
- Financials
Get the detailed quarterly/annual income statement for Vera...
- Holders
Holder Shares Date Reported % Out Value; Price (T.Rowe) New...
- News
The latest news and headlines from Yahoo News. Get breaking...
- Statistics
Find out all the key statistics for Vera Therapeutics, Inc....
- Chart
Interactive Chart for Vera Therapeutics, Inc. (VERA),...
- Analysis
Get a real-time Vera Therapeutics, Inc. (VERA) stock price quote with breaking news, financials, statistics, charts and more.
- 2.22
- 107.85M
- 2.26B
- 54.83M
How much profit does Vera Therapeutics generate each year? Vera Therapeutics (NASDAQ:VERA) has a recorded net income of -$95.99 million. VERA has generated -$2.21 earnings per share over the last four quarters.
- 326 E 8th St, Sioux Falls, 57103, SD
- (844) 978-6257
Get the latest Vera Therapeutics Inc (VERA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Find out all the key statistics for Vera Therapeutics, Inc. (VERA), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Jan 25, 2024 · Vera's Q3 2023 earnings made for somewhat ugly reading, however, with the company reporting a $ (70m) net loss for the year to date, and a cash position of $159m, suggesting the company's funding...
Mar 28, 2023 · For the year ended December 31, 2022, the company reported a net loss of $89.1 million, or a net loss per diluted share of $3.35, compared to a net loss of $32.6 million, or a net loss per diluted share of $2.43, for the same period last year.
